相关实验视频

Updated: Jul 19, 2025

A Novel Method: Super-selective Adrenal Venous Sampling

A Novel Method: Super-selective Adrenal Venous Sampling

Published on: September 15, 2017

基于DNA的生物标志物对上皮癌分类的性能:一个预后研究

Juliane Lippert¹, Ulrich Dischinger¹, Silke Appenzeller²

¹Division of Endocrinology and Diabetes, University Hospital of Würzburg, 97080 Würzburg, Germany.

European journal of endocrinology

|August 17, 2023

概括

基于DNA的生物标志物通过提高S-GRAS评分来改善上腺皮癌 (ACC) 的预后. 这种综合方法为这种罕见的癌症提供了更个性化的患者管理策略.

科学领域:

在瘤学瘤学.
分子诊断学分子诊断
遗传学是一个遗传学.

背景情况:

上皮层癌 (ACC) 是一种罕见且具有攻击性的癌症,结果各不相同.
目前的预后依赖于临床/组织病理学参数 (S-GRAS评分) 和分子生物标志物 (BMs).
基于DNA的BMs对现有得分的额外预后价值需要进一步调查.

研究的目的:

为了比较分析基于DNA的BMs.
评估它们对ACC中的S-GRAS得分的预后附加值.
为了确定分子生物标志物是否可以改善ACC预后.

主要方法:

对194个固定甲,嵌入 (FFPE) ACC样本 (培训和验证队列) 的分析.
针对基因变异和PAX5促进体甲基化进行向DNA测序和热测序.
使用ENSAT的阶段,年龄,症状,切除状态和Ki-67.7计算S-GRAS得分.

主要成果:

Wnt/β-catenin,Rb/p53通路的改变和PAX5高甲基化显示出独立的预后作用 (P < .05对于PFS和DFS).
综合 (COMBI) 评分将基于DNA的BMs与S-GRAS整合在一起,显示出优越的预后歧视.
在两个队伍中,COMBI评分在总体,无进展和无疾病生存方面都超过了单独的S-GRAS.

结论:

有针对性的基于DNA的生物标志物显著提高了ACC预后.
这种分子方法应用于FFPE样本,改善了现有的临床和组织病理学参数.
通过这种综合预后策略,可以推进针对ACC的个性化患者管理.

关键词:

上腺癌是一种上腺癌.分子瘤学分子瘤学个性化药物是个性化的药物.预后预后预后

更多相关视频

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

相关概念视频

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...